

EURONEXT PARIS

14, place des Reflets
92054 Paris La Défense Cedex
France

Alicante, 2th of October 2020

COMMUNICATION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, we inform you about the yearly financial report for 2019 related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

PRIVILEGED INFORMATION

The Company published by means of a Relevant Fact on December 20, 2019, the resolutions adopted by the Extraordinary Shareholders' Meeting held on that date, among which was, as a third point, the delegation to the Board of Directors of the power to issue warrants convertible into shares of the Company in favor of Nice & Green, S.A., with the exclusion of the preferential subscription rights, for a maximum conversion amount of €3,500,000, as well as to increase the share capital in the amount necessary to meet the conversion of such warrants.

Last September, the Board of Directors' resolution adopted on May 8th, 2020, under the delegation of the Company's General Shareholders' Meeting held on December 20th, 2019, was made public, consisting of a third issue of 26,923,077 warrants convertible into shares of the Company for a maximum conversion amount of €1,400,000 (the "Equity Warrants (SEPTEMBER 2020)"), being Nice & Green S.A. ("Nice & Green") the sole addressee of the issue of the Equity Warrants (SEPTEMBER 2020).

Nice & Green, in two communications dated 18 September and 2 October 2020, under the terms of the investment agreement, an agreement communicated to the market by means of a Significant Event dated 18 September 2019, informed the Company and exercised its right to convert 170,182 Equity Warrants (75,329 and 94,853 in each communication) (SEPTEMBER 2020) for a total conversion amount of €900,000.

After this first conversion of the third tranche, Nice & Green still has the right to convert EWs in the amount of 500,000 of the SEPTEMBER 2020 tranche.

As a result of the above, FacePhi will grant a deed of capital increase in order to cover the issue of the equity warrants issued. The new shares of the Company to be issued in execution of the conversion of the 170,182 Equity Warrants (SEPTEMBER 2020) and will be issued, 75,329 with share premium of €5.2700 per share, being the issuing price of these shares €5.3100 Euros per share (€0.04 nominal value plus €5.2700 issue premium) and 94. 853 with a share premium of 5.2313 euros per share, the issuing price for these shares being €5.2713 per share (€0.04 nominal value plus €5.2313 issue premium). Consequently, the Company's share capital will be increased by a nominal amount of €6,807.28 (170,182 * €0.04).

After the aforementioned capital increase, Article 5 of the Company's Articles of Association will be worded as follows: "The share capital is set at the sum of FIVE HUNDRED SEVENTY THREE THOUSAND TWO HUNDRED FIFTEEN EUROS AND TWENTY CENTS (€573,215.20), which is fully subscribed and paid up, divided into FOURTEEN MILLION THREE HUNDRED THIRTY THOUSAND THREE HUNDRED EIGHTY (14. 330,380) shares, represented by book entries, of FOUR CENTS OF EUROPE (0.04 euros) par value each, of the same class, equal, accumulative and indivisible".

The legal regime applicable to the Company's shares is that provided for in Spanish law and, specifically, in the provisions included in the LSC and in Royal Legislative Decree 4/2015, of 23 October, which approves the revised text of the Securities Market Law, as well as in the respective regulations that are applicable.

The newly issued shares are denominated in euros and shall be represented by book entries and shall be registered in the corresponding accounting records in charge of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U., (Iberclear), with domicile in Madrid, Plaza Lealtad nº 1 and of its authorized participating entities.

All the shares, including those issued in this capital increase, are ordinary and confer the same political and economic rights as the shares currently in circulation.

According to the provisions of section 2.2.3 of Circular 2/2020 and in accordance with the terms of the capital increase through the conversion of the equity warrants described herein, the need to publish a Summarised Capital Increase Document (DAR) is excluded.

We remain at your disposal for any clarification you may require.

Sincerely,

Salvador Martí Varó

President of the Board of Directors